Shilpa Medicare has informed that the Subject Expert Committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval to proceed with Phase III clinical trials.
| Subscribe To Our Free Newsletter |
